Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2023
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
85,697
+35.09%
|
-
|
|
Mar 06
2023
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
6,816
-3.89%
|
$54,528
$8.57 P/Share
|
|
Mar 06
2023
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,697
+32.84%
|
-
|
|
Feb 02
2023
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
53,000
+46.41%
|
$0
$0.45 P/Share
|
|
Jan 10
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,130
-1.84%
|
$17,040
$8.58 P/Share
|
|
Jan 09
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
995
-0.85%
|
$7,960
$8.5 P/Share
|
|
Nov 16
2022
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
959
-2.01%
|
$7,672
$8.87 P/Share
|
|
Nov 01
2022
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
31,066
-21.34%
|
$248,528
$8.0 P/Share
|
|
Oct 10
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,284
-1.92%
|
$15,988
$7.13 P/Share
|
|
Oct 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
841
-0.7%
|
$5,887
$7.61 P/Share
|
|
Aug 05
2022
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
17,540
-10.75%
|
$175,400
$10.98 P/Share
|
|
Jul 08
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,300
-1.88%
|
$23,000
$10.47 P/Share
|
|
Jul 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
825
-0.67%
|
$7,425
$9.53 P/Share
|
|
Jun 01
2022
|
Tycho Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
374,688
+50.0%
|
-
|
|
Apr 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
831
-0.67%
|
$10,803
$13.17 P/Share
|
|
Mar 09
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,815
-0.77%
|
$177,780
$12.46 P/Share
|
|
Mar 09
2022
|
Chad M Robins CEO and Chairman |
SELL
Exercise of conversion of derivative security
|
Direct |
14,815
-0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 08
2022
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,582
-3.84%
|
$39,402
$11.44 P/Share
|
|
Mar 08
2022
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,350
-16.32%
|
$36,850
$11.43 P/Share
|
|
Mar 08
2022
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,387
-3.17%
|
$26,257
$11.44 P/Share
|
|
Mar 08
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,815
-0.77%
|
$162,965
$11.38 P/Share
|
|
Mar 08
2022
|
Chad M Robins CEO and Chairman |
SELL
Exercise of conversion of derivative security
|
Direct |
14,815
-0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 07
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
19,239
-0.33%
|
$211,629
$11.92 P/Share
|
|
Mar 07
2022
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
14,815
+0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 07
2022
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,373
-10.37%
|
$28,476
$12.01 P/Share
|
|
Mar 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,244
-1.0%
|
$14,928
$12.01 P/Share
|
|
Mar 07
2022
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,517
-1.43%
|
$54,204
$12.01 P/Share
|
|
Mar 07
2022
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,569
-1.66%
|
$18,828
$12.01 P/Share
|
|
Mar 07
2022
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
220
-0.46%
|
$2,640
$12.01 P/Share
|
|
Mar 07
2022
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
1,569
-2.04%
|
$18,828
$12.01 P/Share
|
|
Mar 07
2022
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
2,670
-2.54%
|
$32,040
$12.01 P/Share
|
|
Mar 07
2022
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
4,613
-2.0%
|
$55,356
$12.01 P/Share
|
|
Mar 04
2022
|
R Mark Adams Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,135
+37.23%
|
-
|
|
Mar 04
2022
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
247,117
+11.4%
|
-
|
|
Mar 04
2022
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
247,117
+43.85%
|
-
|
|
Mar 04
2022
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,135
+43.9%
|
-
|
|
Mar 04
2022
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,186
+46.24%
|
-
|
|
Mar 04
2022
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
61,779
+44.58%
|
-
|
|
Mar 04
2022
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
82,372
+43.9%
|
-
|
|
Mar 04
2022
|
Julie Rubinstein President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
185,338
+44.5%
|
-
|
|
Mar 04
2022
|
Nitin Sood Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
65,898
+28.78%
|
-
|
|
Jan 26
2022
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,021
-1.97%
|
$23,483
$23.32 P/Share
|
|
Dec 22
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-31.64%
|
$300,000
$30.0 P/Share
|